Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions
Open Access
- 19 February 2018
- journal article
- research article
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 3 (1) , 1-5
Abstract
The sale of unproven stem cell interventions (SCIs) by commercial entities has proliferated in highly developed countries, most notably in the USA. Yet, there have been few criminal prosecutions and regulatory enforcement actions against providers who have violated laws and best practice standards due to the lack of resources and legal ambiguity. While the stem cell research community has invested much in protecting patients and preventing the growth of this industry, some patients are seeking remedies under civil law to hold stem cell clinics responsible for fraudulent practices. Several patients have filed lawsuits against providers demanding compensation for physical injuries caused by unproven treatments and financial losses due to fraud and false advertising. Lawsuits can be used as a tool not only to compensate plaintiffs but also to achieve positive public health and policy outcomes. In this paper, we explore the value of a public health litigation strategy as a countermeasure against the exploitative practices of the unproven SCI industry by analyzing stem cell lawsuits and comparing them with other major public health litigation efforts. We argue that stem cell lawsuits complement other approaches to reining in unsafe practices. In particular, stem cell lawsuits could intensify publicity and raise awareness of the harms of unproven treatments, set legal precedent, reshape the media narrative from one focused on the right to try or practice to one highlighting the need for adequate safety and efficacy standards, and encourage authorities to turn their attention to policy reform and enforcement.Keywords
This publication has 24 references indexed in Scilit:
- Open for Business: A Comparative Study of Websites Selling Autologous Stem Cells in Australia and JapanRegenerative Medicine, 2017
- Stem Cells in Court: Historical Trends in US Legal Cases Related to Stem CellsRegenerative Medicine, 2017
- Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMDNew England Journal of Medicine, 2017
- Show drugs work before selling themNature, 2017
- Global Distribution of Businesses Marketing Stem Cell-Based InterventionsCell Stem Cell, 2016
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryCell Stem Cell, 2016
- Recent Court Ruling in Japan Exemplifies Another Layer of Regulation for Regenerative TherapyCell Stem Cell, 2015
- Stem cell tourism – A web-based analysis of clinical services available to international travellersTravel Medicine and Infectious Disease, 2014
- Stem Cell Tourism and Public Education: The Missing ElementsCell Stem Cell, 2014
- Stem Cells2013